Qube Research & Technologies LTD Citius Pharmaceuticals, Inc. Transaction History
Qube Research & Technologies LTD
- $65.7 Billion
- Q3 2024
A detailed history of Qube Research & Technologies LTD transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 72,088 shares of CTXR stock, worth $198,242. This represents 0.0% of its overall portfolio holdings.
Number of Shares
72,088
Previous 230,970
68.79%
Holding current value
$198,242
Previous $133,000
72.93%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CTXR
# of Institutions
53Shares Held
23.4MCall Options Held
83.1KPut Options Held
32.1K-
Armistice Capital, LLC New York, NY7.28MShares$20 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.44MShares$17.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$5.17 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$4.97 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.16MShares$3.19 Million0.0% of portfolio
About Citius Pharmaceuticals, Inc.
- Ticker CTXR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 146,130,000
- Market Cap $402M
- Description
- Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...